tetano
Editor, Senior Moderator
Neurol Sci
. 2021 Nov 22.
doi: 10.1007/s10072-021-05741-x. Online ahead of print.
Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine-a case report
Stefano Consoli[SUP] 1 [/SUP], Fedele Dono[SUP] 2 [/SUP], Giacomo Evangelista[SUP] 1 [/SUP], Maria D'Apolito[SUP] 1 [/SUP], Daniela Travaglini[SUP] 3 [/SUP], Marco Onofrj[SUP] 1 [/SUP], Laura Bonanni[SUP] 4 5 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease-19 (COVID-19) due to acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the largest emergency that humanity had to be dealing with in the last century. During the last months, different types of vaccines have been designed to contain the ongoing SARS-CoV-2 pandemic, with successful results in many countries. Comirnaty (Pfizer/BioNtech) COVID-19 vaccine is a lipid nanoparticle-formulated, nucleoside mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2. Although vaccines have an undeniable efficacy, they can also present several neurological side effects, including headache. According to ICHD-3 Classification, status migrainosus (SMg) is described as a debilitating migraine attack lasting for more than 72 h. Symptoms of SMg can be very severe, preventing the normal daily activities of the individual.
Case presentation: In the present report, we describe a case of SMg that lasted 11 days, time correlated with the second dose of COVID-19 vaccine (Pfizer/Comirnaty) in a 37-year-old woman with a history of migraine without aura.
Conclusions: In patients with a history of migraine, COVID-19 vaccination could lead to a worsening of headache and, in rare cases, to the development of a SMg. This may be related to the inflammatory response that occurs after vaccination.
Keywords: COVID-19; Case report; Comirnaty BNT162b2; Migraine without aura; Status migrainosus.
. 2021 Nov 22.
doi: 10.1007/s10072-021-05741-x. Online ahead of print.
Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine-a case report
Stefano Consoli[SUP] 1 [/SUP], Fedele Dono[SUP] 2 [/SUP], Giacomo Evangelista[SUP] 1 [/SUP], Maria D'Apolito[SUP] 1 [/SUP], Daniela Travaglini[SUP] 3 [/SUP], Marco Onofrj[SUP] 1 [/SUP], Laura Bonanni[SUP] 4 5 [/SUP]
Affiliations
- PMID: 34807361
- DOI: 10.1007/s10072-021-05741-x
Abstract
Background: Coronavirus disease-19 (COVID-19) due to acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the largest emergency that humanity had to be dealing with in the last century. During the last months, different types of vaccines have been designed to contain the ongoing SARS-CoV-2 pandemic, with successful results in many countries. Comirnaty (Pfizer/BioNtech) COVID-19 vaccine is a lipid nanoparticle-formulated, nucleoside mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2. Although vaccines have an undeniable efficacy, they can also present several neurological side effects, including headache. According to ICHD-3 Classification, status migrainosus (SMg) is described as a debilitating migraine attack lasting for more than 72 h. Symptoms of SMg can be very severe, preventing the normal daily activities of the individual.
Case presentation: In the present report, we describe a case of SMg that lasted 11 days, time correlated with the second dose of COVID-19 vaccine (Pfizer/Comirnaty) in a 37-year-old woman with a history of migraine without aura.
Conclusions: In patients with a history of migraine, COVID-19 vaccination could lead to a worsening of headache and, in rare cases, to the development of a SMg. This may be related to the inflammatory response that occurs after vaccination.
Keywords: COVID-19; Case report; Comirnaty BNT162b2; Migraine without aura; Status migrainosus.